TrialDiabetes, obesity & metabolism2026

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk.

Elias John Elenjickal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.